Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | REN | P00797 | 1/20 | 0.37 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.37 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.37 |
| ▸ | PREP | P48147 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL994990 | 1.00 | NR1H2 (0.50) | NR1H2HPGDMAPTMEN1ALDH1A1 | |
| SCHEMBL1462710 | 1.00 | NR1H2 (0.50) | NR1H2HPGDMAPTMEN1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL1162050 | 0.98 | NR1H2 (0.49) | NR1H2HPGDMAPTMEN1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL1162048 | 0.98 | NR1H2 (0.49) | NR1H2HPGDMAPTMEN1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL14150192 | 0.98 | NR1H2 (0.49) | NR1H2HPGDMAPTMEN1ALDH1A1 | |
| SCHEMBL28078177 | 0.92 | NR1H2 (0.44) | NR1H2HPGDMAPTMEN1ALDH1A1 | |
| SCHEMBL28078175 | 0.92 | NR1H2 (0.44) | NR1H2HPGDMAPTMEN1ALDH1A1 | |
| SCHEMBL17258176 | 0.91 | NR1H2 (0.48) | NR1H2HPGDMAPTMEN1ALDH1A1 | |
| SCHEMBL12836933 | 0.88 | CA1 (0.45) | NR1H2HPGDMAPTMEN1ALDH1A1 | |
| SCHEMBL14720039 | 0.88 | CA1 (0.45) | NR1H2HPGDMAPTMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 786 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4504777-A1 | COMBINATION OF A GREMLIN-1 ANTAGONIST WITH AN INHIBITOR OF RAS-RAF-MEK-ERK SIGNALLING | UCB Biopharma SRL (BE) | 2025-02-12 | — | — | EP | claimed |
| WO-2023194583-A1 | COMBINATION OF A GREMLIN-1 ANTAGONIST WITH AN INHIBITOR OF RAS-RAF-MEK-ERK SIGNALLING | UCB Biopharma SRL (BE) | 2023-10-12 | — | — | WO | claimed |
| CN-114349711-A | Synthesis method of (R) -1-Boc-3-hydroxymethyl piperazine | 四川恒康科技发展有限公司 | 2022-04-15 | — | — | CN | claimed |
| CN-104046246-B | The chemical-mechanical planarization of tungsten-containing substrate | 气体产品与化学公司 | 2016-06-15 | — | — | CN | claimed |
| US-20140273458-A1 | Chemical Mechanical Planarization for Tungsten-Containing Substrates | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2014-09-18 | — | — | US | claimed |
| EP-2779217-A2 | Chemical mechanical planarization for tungsten-containing substrates | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2014-09-17 | — | — | EP | claimed |
| CN-104046246-A | Chemical Mechanical Planarization for Tungsten-Containing Substrates | AIR PROD & CHEM | 2014-09-17 | — | — | CN | claimed |
| CN-122036605-A | Antagonists of GPR39 proteins | 俄勒冈健康科学大学 | 2026-05-15 | — | — | CN | disclosed |
| US-20260124205-A1 | MODULATORS OF BETA CATENIN AND USES THEREOF | DEWPOINT THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4294800-B1 | APOL1 INHIBITORS AND METHODS OF USE | MAZE THERAPEUTICS INC (US) | 2026-05-06 | — | — | EP | disclosed |
| WO-2026090104-A1 | MODULATORS OF BETA CATENIN AND USES THEREOF | DEWPOINT THERAPEUTICS, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| EP-4722219-A1 | CEREBELLAR PROTEIN E3 UBIQUITIN LIGASE INHIBITOR AND CHIMERIC COMPOUND TARGETING PROTEIN DEGRADATION | Gan & Lee Pharmaceuticals Co., Ltd. (CN) | 2026-04-08 | — | — | EP | disclosed |
| US-12595265-B2 | Inhibitors of activin receptor-like kinase | BLUEPRINT MEDICINES CORPORATION (US) | 2026-04-07 | — | — | US | disclosed |
| EP-1280798-A1 | BICYCLIC HETEROCYLCES, MEDICAMENTS CONTAINING SAID COMPOUNDS, THE USE THEREOF AND METHOD FOR PRODUCING THEM | Boehringer Ingelheim Pharma KG (DE) | 2003-02-05 | — | — | EP | disclosed |
| US-20020049197-A1 | Aminoquinazolines and their use as medicaments | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-04-25 | — | — | US | disclosed |
| EP-1187828-A1 | QUINOLINE DERIVATIVES AS ANTIBACTERIALS | SMITHKLINE BEECHAM PLC (GB) | 2002-03-20 | — | — | EP | disclosed |
| WO-2002018372-A1 | BICYCLIC HETEROCYCLES, MEDICAMENTS CONTAINING THESE COMPOUNDS, THEIR USE, AND METHODS FOR THE PRODUCTION THEREOF | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-03-07 | — | — | WO | disclosed |
| US-20010044435-A1 | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2001-11-22 | — | — | US | disclosed |
| WO-2001077104-A1 | BICYCLIC HETEROCYLCES, MEDICAMENTS CONTAINING SAID COMPOUNDS, THE USE THEREOF AND METHOD FOR PRODUCING THEM | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2001-10-18 | — | — | WO | disclosed |
| WO-2000078748-A1 | QUINOLINE DERIVATIVES AS ANTIBACTERIALS | SMITHKLINE BEECHAM P.L.C. (GB) | 2000-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049197-A1 | Aminoquinazolines and their use as medicaments | JAK1, ABL1, JAK2 | NR1H2 1294/4885HPGD 1516/4885MAPT 2527/4885 |
| US-20260124205-A1 | MODULATORS OF BETA CATENIN AND USES THEREOF | CTNNB1, CTNNA1, CTNND1 | NR1H2 37/4885HPGD 3936/4885MAPT 4207/4885 |
| US-20010044435-A1 | Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them | RET, BMX, CYP11B1 | NR1H2 598/4885HPGD 1127/4885MAPT 1684/4885 |
| US-12595265-B2 | Inhibitors of activin receptor-like kinase | ACVR1, ACVRL1, ACVR2A | NR1H2 196/4885HPGD 4015/4885MAPT 4748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.